The biggest challenge for the industry in Canada is the unpredictability of the marketplace. That puts a huge risk on the industry.
Also, keep in mind that with special access programs, basically the accountability is entirely on the industry to provide medicines for free. I think that really deters innovation as a whole, whether it is related to antimicrobial resistance or other disease areas of unmet medical need.